Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial

Thrombosis Research

Volumn 139, Issue , 2016, Pages 77-81

  Douketis, James D ^a,i   Healey, Jeff S ^a,b   Brueckmann, Martina ^c,e   Fraessdorf, Mandy ^c   Spyropoulos, Alex C ^d   Wallentin, Lars ^g   Oldgren, Jonas ^g   Reilly, Paul ^h   Ezekowitz, Michael D ^f   Connolly, Stuart J ^a,b   Yusuf, Salim ^a,b   Eikelboom, John W ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g UPPSALA UNIVERSITY   (Sweden)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁱ Joseph's Healthcare   (Canada)

Author keywords

Dabigatran; Perioperative; Urgent surgery; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ELECTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; ADVERSE EFFECTS; AMBULATORY CARE; CHEMICALLY INDUCED; COMPLICATION; SURGERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTICOAGULANTS; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; MALE; PERIOPERATIVE PERIOD; SURGICAL PROCEDURES, OPERATIVE; THROMBOEMBOLISM; WARFARIN;

EID: 84960155889     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.01.004     Document Type: Article

References (27)

1. D. Siegal, J. Yudin, S. Kaatz, J.D. Douketis, W. Lim, and A.C. Spyropoulos Periprocedural heparin bridging in patients receiving vitamin K antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates Circulation 126 13 2012 1630 1639
2. D. Garcia, J.H. Alexander, L. Wallentin, D.M. Wojdyla, L. Thomas, M. Hanna, S.M. Al-Khatib, P. Dorian, J. Ansell, P. Commerford, G. Flaker, F. Lanas, D. Vinereanu, D. Xavier, E.M. Hylek, C. Held, F.W. Verheugt, C.B. Granger, and R.D. Lopes Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures Blood 124 25 2014 3692 3698
3. M.W. Sherwood, J.D. Douketis, M.R. Patel, J.P. Piccini, A.S. Hellkamp, Y. Lokhnygina, A.C. Spyropoulos, G.J. Hankey, D.E. Singer, C.C. Nessel, K.W. Mahaffey, K.A. Fox, R.M. Califf, R.C. Becker, and ROCKET AF Investigators Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) Circulation 129 18 2014 1850 1859
4. J.S. Healey, J. Eikelboom, J. Douketis, L. Wallentin, J. Oldgren, S. Yang, E. Themeles, H. Heidbuchel, A. Avezum, P. Reilly, S.J. Connolly, S. Yusuf, M. Ezekowitz, and RE-LY investigators Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial Circulation 126 3 2012 343 348
5. B.A. Steinberg, E.D. Peterson, S. Kim, L. Thomas, B.J. Gersh, G.C. Fonarow, P.R. Kowey, K.W. Mahaffey, M.W. Sherwood, P. Chang, J.P. Piccini, and J. Ansell Outcomes registry for better informed treatment of atrial fibrillation investigators and patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: Findings from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) Circulation 131 5 2015 488 494
6. J. Beyer-Westendorf, V. Gelbricht, K. Forster, F. Ebertz, C. Kohler, S. Werth, E. Kuhlisch, T. Stange, C. Thieme, K. Daschkow, and N. Weiss Peri-interventional management of novel oral anticoagulants in daily care: Results from the prospective Dresden NOAC registry Eur. Heart J. 35 28 2014 1888 1896
7. P.J. Devereaux, L. Goldman, S. Yusuf, K. Gilbert, K. Leslie, and G.H. Guyatt Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: A review CMAJ 173 7 2005 779 788
8. Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study I, P.J. Devereaux, M.T. Chan, P. Alonso-Coello, M. Walsh, O. Berwanger, C.Y. Wang, R.I. Garutti, M.J. Jacka, A. Sigamani, S. Srinathan, B.M. Biccard, C.K. Chow, V. Abraham, M. Tiboni, S. Pettit, W. Szczeklik, G. Lurati Buse, F. Botto, G. Guyatt, and et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery JAMA 307 21 2012 2295 2304
9. R. Sarode, T.J. Milling Jr., M.A. Refaai, A. Mangione, A. Schneider, B.L. Durn, and J.N. Goldstein Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study Circulation 128 11 2013 1234 1243
10. S. Kaatz, P.A. Kouides, D.A. Garcia, A.C. Spyropolous, M. Crowther, J.D. Douketis, A.K. Chan, A. James, S. Moll, T.L. Ortel, E.M. Van Cott, and J. Ansell Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Am. J. Hematol. 87 Suppl. 1 2012 S141 S145
11. D. Faraoni, J.H. Levy, P. Albaladejo, C.M. Samama, and Groupe d'interet en hemostase P Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants Crit. Care 19 2015 203
12. M.N. Lauw, M. Coppens, and J.W. Eikelboom Recent advances in antidotes for direct oral anticoagulants: Their arrival is imminent Can J Cardiol. 30 4 2014 381 384
13. D.M. Siegal, and A. Cuker Reversal of target-specific oral anticoagulants Drug Discov. Today 19 9 2014 1465 1470
14. A. Cuker, D.M. Siegal, M.A. Crowther, and D.A. Garcia Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants J. Am. Coll. Cardiol. 64 11 2014 1128 1139
15. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis J. Thromb. Haemost. 2013
16. A. Majeed, K. Meijer, R. Larrazabal, F. Arnberg, G.J. Luijckx, R.S. Roberts, and S. Schulman Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate Thromb. Haemost. 111 2 2014 233 239
17. C.V. Pollack Jr., P.A. Reilly, J. Eikelboom, S. Glund, P. Verhamme, R.A. Bernstein, R. Dubiel, M.V. Huisman, E.M. Hylek, P.W. Kamphuisen, J. Kreuzer, J.H. Levy, F.W. Sellke, J. Stangier, T. Steiner, B. Wang, C.W. Kam, and J.I. Weitz Idarucizumab for dabigatran reversal N. Engl. J. Med. 373 6 2015 511 520
18. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, and A. Wallentin Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 12 2009 1139 1151
19. J.D. Douketis, A.C. Spyropoulos, F.A. Spencer, M. Mayr, A.K. Jaffer, M.H. Eckman, A.S. Dunn, and R. Kunz Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e326S e350S
20. A.C. Spyropoulos, J.D. Douketis, G. Gerotziafas, S. Kaatz, T.L. Ortel, and S. Schulman Subcommittee on the control of anticoagulation of the SSC of the ISTH. Periprocedural antithrombotic and bridging therapy: Recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy J. Thromb. Haemost. 10 4 2012 692 694
21. C.C. Acevedo, F. Velasco, and C. Herrera Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery Futur. Cardiol. 1-5 2015
22. T. Puttick, R. Bahl, and H. Mohamedbhai Emergency reversal of dabigatran for emergency surgery BMJ Case Rep. 2015 2015
23. I. Roberts, H. Shakur, K. Ker, T. Coats collaborators C-T Antifibrinolytic drugs for acute traumatic injury Cochrane Database Syst. Rev. 1 2011 CD004896
24. E. Simpson, Y. Lin, S. Stanworth, J. Birchall, C. Doree, and C. Hyde Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia Cochrane Database Syst. Rev. 3 2012 CD005011
25. A. Coppola, J. Windyga, A. Tufano, C. Yeung, and M.N. Di Minno Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery Cochrane Database Syst. Rev. 2 2015 CD009961
26. O. Grottke, R. Rossaint, Y. Henskens, R. van Oerle, H. Ten Cate, and H.M. Spronk Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model PLoS ONE 8 5 2013 e64100
27. F. Dentali, C. Marchesi, M. Giorgi Pierfranceschi, M. Crowther, D. Garcia, E. Hylek, D.M. Witt, N.P. Clark, A. Squizzato, D. Imberti, and W. Ageno Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis Thromb. Haemost. 106 3 2011 429 438